You are here
Long-Acting Insulin Analogue Garners FDA Approval
"The US approval of Levemir® is an important event for Novo Nordisk in the US as it completes our portfolio of insulin analogues and thereby paves the way for continued expansion of our US diabetes care franchise," says Kåre Schultz, executive vice president and chief operating officer.
In addition to the US approval, Levemir® has already been approved for use in 37 countries, including the countries in the European Union. The product has been introduced in 11 European markets, with additional launches expected during the second half of 2005.
Levemir® is a soluble, long-acting basal human insulin analogue with a relatively flat action profile and prolonged duration of action of up to 24 hours. Levemir® is indicated for once or twice-daily subcutaneous administration in the treatment of adult patients with diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycaemia. Levemir® can be used as the basal component of basal-bolus therapy in type 1 and type 2 diabetes and as add-on therapy in people with type 2 diabetes who are inadequately controlled on oral antidiabetic agents. The file on use in paediatrics is under review with the FDA and a decision is expected before the end of 2005.
Novo Nordisk expects to introduce Levemir® in the US market within the next 12 months. The approval of Levemir® does not change Novo Nordisk's expectations for the financial results for 2005.
Source: Novo Nordisk